Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on June 16, 2017, primarily to report on the presentation of updated clinical data for its Bruton's Tyrosine Kinase (BTK) inhibitor, BGB-3111, at the 14th International Conference on Malignant Lymphoma (14-ICML). This included data from a Phase 1 trial in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as data in Waldenström’s macroglobulinemia. The company also announced initial data on BGB-3111 in combination with obinutuzumab for certain lymphoma types.
Key Highlights
- 1BeOne Medicines (ONC) presented updated clinical data for its BTK inhibitor BGB-3111 at the 14-ICML conference.
- 2Data presented included results from a Phase 1 trial in patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
- 3Updated data for BGB-3111 in Waldenström’s macroglobulinemia was also presented.
- 4Initial clinical data on BGB-3111 combined with obinutuzumab in CLL, SLL, and follicular lymphoma was announced.
- 5The company filed three press releases as exhibits detailing these clinical updates.
- 6BeOne Medicines is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Frequently Asked Questions
The main focus of this 8-K filing is to announce and provide access to updated clinical data for BeOne Medicines' BTK inhibitor, BGB-3111, presented at the 14th International Conference on Malignant Lymphoma (14-ICML).
The presented data included patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia, and follicular lymphoma. Some data also covered combinations of BGB-3111 with obinutuzumab.
BGB-3111 is BeOne Medicines' Bruton's Tyrosine Kinase (BTK) inhibitor, a drug candidate being evaluated in clinical trials for various hematological malignancies.
As an emerging growth company, BeOne Medicines is subject to certain regulatory and disclosure accommodations under the JOBS Act, which can include extended transition periods for adopting new accounting standards, though in this case, they have elected not to use that extension.